Mustang Bio (MBIO) Competitors $2.39 -0.03 (-1.24%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.31 -0.08 (-3.35%) As of 07:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO vs. PEPG, ACRV, KPTI, BRNS, ATHE, ELYM, RANI, ITRM, PLUR, and STTKShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include PepGen (PEPG), Acrivon Therapeutics (ACRV), Karyopharm Therapeutics (KPTI), Barinthus Biotherapeutics (BRNS), Alterity Therapeutics (ATHE), Eliem Therapeutics (ELYM), Rani Therapeutics (RANI), Iterum Therapeutics (ITRM), Pluri (PLUR), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Its Competitors PepGen Acrivon Therapeutics Karyopharm Therapeutics Barinthus Biotherapeutics Alterity Therapeutics Eliem Therapeutics Rani Therapeutics Iterum Therapeutics Pluri Shattuck Labs Mustang Bio (NASDAQ:MBIO) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Is MBIO or PEPG more profitable? Mustang Bio's return on equity of 0.00% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets Mustang BioN/A N/A -80.79% PepGen N/A -81.26%-63.65% Which has more risk & volatility, MBIO or PEPG? Mustang Bio has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Do analysts recommend MBIO or PEPG? PepGen has a consensus price target of $7.67, indicating a potential upside of 518.28%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher valuation & earnings, MBIO or PEPG? PepGen is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMustang BioN/AN/A-$15.75M-$78.00-0.03PepGenN/AN/A-$89.98M-$3.13-0.40 Does the media favor MBIO or PEPG? In the previous week, PepGen had 14 more articles in the media than Mustang Bio. MarketBeat recorded 17 mentions for PepGen and 3 mentions for Mustang Bio. PepGen's average media sentiment score of 0.12 beat Mustang Bio's score of 0.08 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mustang Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of MBIO or PEPG? 9.9% of Mustang Bio shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 0.2% of Mustang Bio shares are held by insiders. Comparatively, 4.6% of PepGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPepGen beats Mustang Bio on 9 of the 13 factors compared between the two stocks. Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.59M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.0320.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book-1.137.568.145.54Net Income-$15.75M-$55.11M$3.24B$257.73M7 Day Performance-23.15%3.81%0.18%-0.08%1 Month Performance115.32%11.60%5.96%8.09%1 Year Performance-88.19%-2.11%26.24%13.02% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio1.1271 of 5 stars$2.39-1.2%N/A-87.9%$10.59MN/A-0.03100Gap DownPEPGPepGen3.0862 of 5 stars$1.29+2.4%$7.67+494.3%-92.5%$42.21MN/A-0.4130ACRVAcrivon Therapeutics3.7384 of 5 stars$1.33+0.8%$17.71+1,231.9%-82.9%$41.70MN/A-0.6058Positive NewsKPTIKaryopharm Therapeutics3.9673 of 5 stars$4.77+4.8%$37.40+684.1%-70.8%$41.21M$145.24M-0.36380High Trading VolumeBRNSBarinthus Biotherapeutics3.2108 of 5 stars$1.02+2.0%$6.25+512.7%-34.0%$41.15M$14.97M-0.62107ATHEAlterity Therapeutics2.1591 of 5 stars$4.63+0.9%$12.00+159.2%+122.4%$41.07MN/A0.0010ELYMEliem TherapeuticsN/A$1.37+1.5%N/A-79.7%$40.76MN/A-2.589RANIRani Therapeutics1.9902 of 5 stars$0.70+8.4%$7.33+950.0%-89.2%$40.15M$1.20M-0.71110News CoverageGap DownHigh Trading VolumeITRMIterum Therapeutics2.0561 of 5 stars$1.00-11.5%$9.00+800.0%-38.0%$40MN/A-1.0110Positive NewsGap UpPLURPluri3.2875 of 5 stars$5.08-4.3%$12.00+136.2%-6.4%$39.79M$1.03M-0.92150Gap DownSTTKShattuck Labs3.7027 of 5 stars$0.82+0.6%$7.50+814.6%-82.8%$39.28M$5.72M-0.59100News CoveragePositive News Related Companies and Tools Related Companies PEPG Alternatives ACRV Alternatives KPTI Alternatives BRNS Alternatives ATHE Alternatives ELYM Alternatives RANI Alternatives ITRM Alternatives PLUR Alternatives STTK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBIO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBIO Stock Alerts